Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Time to Sell?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $8.91, but opened at $8.29. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.51, with a volume of 7,693 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SGIOY. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.6%

The stock has a market cap of $14.76 billion, a PE ratio of 10.84, a PEG ratio of 3.30 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The company has a 50 day moving average price of $9.80 and a two-hundred day moving average price of $9.89.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%.The company had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.